Patents by Inventor Yongkai Li

Yongkai Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS
    Publication number: 20170057968
    Abstract: The invention provides a compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.
    Type: Application
    Filed: April 29, 2015
    Publication date: March 2, 2017
    Applicant: NOVARTIS AG
    Inventors: Yongkai LI, Tingting MO, Porino VA, Tom Yao-Hsiang WU, Xiaoyue ZHANG
  • COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS
    Publication number: 20170044168
    Abstract: The invention provides a compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.
    Type: Application
    Filed: April 29, 2015
    Publication date: February 16, 2017
    Applicant: NOVARTIS AG
    Inventors: Alex CORTEZ, Timothy HOFFMAN, Yongkai LI, Tom Yao-Hsiang WU, Xiaoyue ZHANG
  • ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS
    Publication number: 20160213776
    Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.
    Type: Application
    Filed: April 7, 2016
    Publication date: July 28, 2016
    Applicant: GlaxoSmithKline Biologicals SA
    Inventors: Manmohan SINGH, David A.G. SKIBINKSI, Tom Yao-Hsiang WU, Yongkai LI, Alex CORTEZ, Xiaoyue ZHANG, Yefen ZOU, Timothy Z. HOFFMAN, Jianfeng PAN, Kathy YUE
  • Adsorption of immunopotentiators to insoluble metal salts
    Patent number: 9315530
    Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminum salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.
    Type: Grant
    Filed: September 1, 2011
    Date of Patent: April 19, 2016
    Assignee: Novartis AG
    Inventors: Manmohan Singh, David A. G. Skibinski, Tom Yao-Hsiang Wu, Yongkai Li, Alex Cortez, Xiaoyue Zhang, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan, Kathy Yue
  • COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS
    Publication number: 20150225432
    Abstract: The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.
    Type: Application
    Filed: April 24, 2015
    Publication date: August 13, 2015
    Applicant: Novartis AG
    Inventors: Alex Cortez, Yongkai Li, Manmohan Singh, David Skibinski, Kathy Yue, Tom Yao-Hsiang Wu, Xiaoyue Zhang
  • Compounds and compositions as TLR activity modulators
    Patent number: 9045470
    Abstract: The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: June 2, 2015
    Assignee: IRM LLC
    Inventors: Tom Yao Hsiang Wu, Yongkai Li, Alex Cortez, Kathy Yue, Xiaoyue Zhang, Manmohan Singh, David Skibinski
  • Compounds and compositions as TLR activity modulators
    Patent number: 8895577
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is —CR4?CR5.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: November 25, 2014
    Inventors: Tom Yao-Hsiang Wu, Yongkai Li, Alex Cortez, Yefen Zou, Pranab Mishra, Xiaoyue Zhang, Nicholas Valiante
  • ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS
    Publication number: 20130274465
    Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.
    Type: Application
    Filed: September 1, 2011
    Publication date: October 17, 2013
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Manmohan Singh, David A.G. Skibinski, Tom Yao-Hsiang Wu, Yongkai Li, Alex Cortez, Xiaoyue Zhang, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan, Kathy Yue
  • COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS
    Publication number: 20130253002
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is —CR4?CR5.
    Type: Application
    Filed: April 22, 2013
    Publication date: September 26, 2013
    Inventors: TOM YAO-HSIANG WU, YONGKAI LI, ALEX CORTEZ, YEFEN ZOU, PRANAB MISHRA, XIAOYUE ZHANG, NICHOLAS VALIANTE
  • Compounds and compositions as TLR activity modulators
    Patent number: 8466167
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is —CR4?CR5.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: June 18, 2013
    Assignees: IRM LLC, Novartis AG
    Inventors: Tom Yao Hsiang Wu, Yongkai Li, Alex Cortez, Yefen Zou, Pranab Mishra, Xiaoyue Zhang, David Skibinski, Manmohan Singh, Nicholas Valiante
  • Formulation of immunopotentiators
    Publication number: 20120177681
    Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.
    Type: Application
    Filed: September 1, 2011
    Publication date: July 12, 2012
    Inventors: Manmohan Singh, David A.G. Skibinski, Tom Yao-Hsiang Wu, Yongkai Li, Alex Cortez, Xiaoyue Zhang, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan, Kathy Yue
  • COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS
    Publication number: 20110081365
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is —CR4?CR5.
    Type: Application
    Filed: February 27, 2009
    Publication date: April 7, 2011
    Applicants: IRM LLC, Novartis 35
    Inventors: Alex Cortez, Yongkai Li, Pranab Mishra, Manmohan Singh, David Skibinski, Nicholas Valiante, Tom Yao-Hsiang Wu, Xiaoyue Zhang, Yefen Zou
  • COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS
    Publication number: 20110053893
    Abstract: The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.
    Type: Application
    Filed: September 1, 2010
    Publication date: March 3, 2011
    Applicants: IRM LLC, Novartis AG
    Inventors: Tom Yao Hsiang Wu, Yongkai Li, Alex Cortez, Kathy Yue, Xiaoyue Zhang, Manmohan Singh, David Skibinski
  • Glucocorticoid Receptor Modulator Compounds and Methods
    Publication number: 20090105292
    Abstract: Disclosed herein are compounds of Formula I: and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof. Certain of such compounds are selective glucocorticoid receptor modulators and/or selective glucocorticoid binding agents. Also disclosed are methods of making and using such compounds, including, but not limited to, using such compounds for treating various conditions.
    Type: Application
    Filed: February 24, 2005
    Publication date: April 23, 2009
    Applicant: LIGAND PHARMACEUTICALS INCORPORATED
    Inventors: Lin Zhi, Robert Ardecky, Dean Phillips, John Tyhonas, Donald Karanewsky, Robert Higuchi, A.R. Hudson, S.L. Roach, A.C. Vassar, Yongkai Li, Mark Adams, L.J. Valdez, C. Cuervo